Find an expert

Stefan is a Staff Specialist in Neurology at the Princess Alexandra Hospital (PAH) and the Mater Centre for Neuroscience. He finished his training as neurologist in 2012.

He runs dedicated multiple sclerosis (MS) and Neuroimmunology clinics at the PAH, leading in modern MS therapies. Moreover, he has been at the forefront of advancing the field of neuroimmunology in Queensland, with establishment of dedicated neuroimmunology outpatient clinics at the RBWH and PAH, combining expertise from neurologists and immunologists in the care of this very complex group of disorders.

In addition to his busy, full-time clinical workload, Stefan has been involved as PI or CI in a range of clinical trials in the fields of MS, botulinum toxin, CIDP and Pompe’s disease. Additionally, he has performed and is involved in ongoing research projects of neuroimmunological disorders such as neuromyelitis optica, myasthenia gravis and autoimmune limbic encephalitis. He has been a member of the New Horizons study to assess prevalence of anti-neuronal antibodies in patients with new onset psychosis.

Prior to this, Stefan finished a PhD in the field of ‘Immunogenetics of Guillain-Barre Syndrome and Chronic inflammatory polyneuropathy’ at the University of Queensland in 2014. He also completed a doctoral thesis at the University of Heidelberg, Germany in 2002 in the field of T cell immunology. During this time, he has developed solid skills in bench-side immunological research.

Currently, he is neurological lead in a diverse group of clinicians and scientists investigating the role of antineuronal antibodies in neurological and psychiatric disease. He supervises 3 PhD students in the field of advanced imaging in autoimmune encephalitis and multiple sclerosis. He is currently building up a laboratory to test antineuronal antibodies using live cell assays.

Dr. Borg is a translational scientist with a career spanning both Germany and Australia. She has amassed extensive expertise in cellular biology in regenerative therapies, as well as molecular biology, biochemical, and preclinical methodology in diabetes research. Her leadership in coordinating the newest Queensland longitudinal birth cohort has honed her skills in multidisciplinary teamwork, scientific communication, databank governance and epidemiological study design.

Passionate about innovation, Dr. Borg excels in leveraging communication, engagement, and partnerships to address persistent challenges in clinical research. As a Principal Research Fellow in the Women-Newborn-Children's Services at Gold Coast Hospital and Health Service, she is dedicated to workforce capacity building and integrating clinical expertise with academic knowledge. Her efforts are focused on enhancing research implementation and improving health service evaluation within cross-disciplinary teams, to prioritise healthcare improvement.

Associate Professor Emma Hamilton-Williams’ career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.

In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.

She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.

She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.

Dr. Sherman Leung is the Head of Research Operations at Wesley Research Institute - the research partner of UnitingCare. UnitingCare is the largest private employer in Queensland, encompassing four hospitals (The Wesley Hospital, St. Andrew's War Memorial Hospital, Buderim Private Hospital and St. Stephen's Hospital), as well as significant community-based offerings through Lifeline, Blue Care, Family and Disability Services, and ARRCS.

Dr. Leung is a PhD trained scientist, conducting his research training at Mater Research Institute, The University of Queensland, during which his research was published in highly regarded peer-reviewed journals, including in 'Diabetes', receiving the Cover Image, an 'In This Issue' feature, and shared across the Australian-wide 7 Network news.

He has extensive experience in clinical trials, having worked at Microba Life Sciences, an ASX-listed biotechnology start-up, and Nucleus Network, Australia’s largest early phase clinical trial site having overseen the conduct of several high-profile COVID-19 projects including Nuvaxovid by Novavax that has been granted emergency authorisation in 40 countries including by the TGA, EMEA & FDA.

He contributes his spare time to the greater good through numerous initiatives in the industry including being a Board Director of the Australian Clinical Trials Alliance (ACTA), Editorial Board for 'Trials' – a BMC journal promoting all aspects of trials including methods, processes and non-significant outcomes for transparency in the field – being a former member of the Metro North Human Research Ethics Committee (HREC), and offering regular guest classrooms on clinical trials, informed consent and ethics at The University of Queensland.

Dr. Kelvin Tuong is a Senior Research Fellow/Group Leader at the Ian Frazer Centre for Children’s Immunotherapy Research (IFCCIR), Child Health Research Centre. He is interested in single-cell analysis of immune cells and harnessing adaptive immune receptors for understanding immune cell development and function in health and in cancer.

Dr. Tuong was born and raised in Singapore and moved to Brisbane, Australia, after completing national service in Singapore and obtaining a Diploma in Biomedical Laboratory Technology (Ngee Ann Polytechnic).

Dr. Tuong was originally trained as a molecular cell biologist and gradually transitioned into bioinformatics during his post-doctoral training. He has been very prolific for an early career researcher, having published >50 articles since 2013, with nearly a third of them as first/co-first or last author and has a stellar track record of pushing out highly collaborative work in prestigious journals including Nature, Cell, Science, Nature Medicine, Nature Biotechnology J Exp Med etc. He has the rare combination of having excellent laboratory and bioinformatics skill sets which provide him a strong command of both fundamental immunology and computational approaches.

Dr. Tuong completed his undergraduate Bachelor's degree in Biomedical science with Class I Honours, followed by his PhD in macrophage cell biology and endocrinology at UQ (Prof. Jenny Stow lab and Emiritus Prof. George Muscat lab, IMB, UQ). He then went on to a post-doc position with Emiritus Prof. Ian Frazer (co-inventor of the Gardasil cervical cancer vaccine, UQ Frazer Institute, Translational Research Institute) where he worked on HPV immunology, cervical cancer and skin cancer. In his time in the Frazer lab, he developed an interest in bioinformatics analyses as a means to tackle and understanding immunology problems in health and disease. He then moved to the UK and joined Prof. Menna Clatworthy's lab at the University of Cambridge and Dr. Sarah Teichmann's lab at the Wellcome Trust Sanger Institute. He has focused his interests on single-cell analyses of tissue immune cells, including T and B cells and their specific receptors (TCR/BCR). He has developed bespoke bioinformatics software, including one tailored for single-cell B Cell Receptor sequencing analysis, Dandelion, which he used in one of the largest combined single-cell transcriptomic, surface proteomic and TCR/BCR sequencing dataset in the world, published in Nature Medicine, and more recently in Nature Biotechnology where we introduced a TCR-based pseudotime trajectory analysis method.

Dr. Tuong is now leading the Computational Immunology group at the IFCCIR and his lab is focused on investigating how pediatric immunity is perturbed during cancer at the cellular level and how this information can be used for creating novel warning systems for children with cancer. For potential students/post-docs/trainees interested in joining the team, please contact Dr. Tuong at z.tuong@uq.edu.au.

Dr Ran Wang graduated with her PhD in 2015, and after undertaking a postdoc position in Scripps Research, USA returned to Australia in 2017. She is now a Senior Postdoctoral Researcher supported by the prestigious Bushell Postdoctoral Research Fellowship from the Gastroenterology Society of Australia. Dr Wang is interested to understand the nature of inflammation in gut and lung and investigate the local and systemic impacts of chronic gut inflammation. In addition to a growing track-record in the mucosal immunology field, she is also building an inter-disciplinary research profile in material science and nanotechnology for drug delivery and immune modulation. She is the Associate Editor of Frontier of Cellular and Infection Microbiology Journal since 2018.